IDENTIFICATION AND BIOINFORMATICS ANALYSIS OF TWO NOVEL VARIANTS IN THE SEMA4A AND SCP2 GENES IN A PATIENT WITH EARLY-ONSET VISUAL IMPAIRMENT AND LEUKODYSTROPHY.

Main Article Content

Hossein Ahmed Hashim
Mortaza Bonyadi
Abbas Rafat

Keywords

SEMA4A gene, SCP2 gene, Whole Exome Sequencing, (NM_001193300.2):c.2272-2273insT, (NM_002979.5):c.712A>T

Abstract

Optic Nerve Atrophy (ONA) is the destruction of the nerve fibers of the optic nerve, reducing the number of retinal ganglion cells that generate nerve impulses and transmit them from the eye to the brain. In this case, the information arriving in the brain is distorted, which is accompanied by deterioration of vision and can lead to irreversible blindness.


We conducted a genetic analysis of a six-year-old male patient with vision problems, cognitive impairment and leukodystrophy. DNA samples were collected from the patient and his mother and father. Whole-genome sequencing (WES) and PCR-Sanger sequencing were used to identify genetic variants. Two novel mutation variants were detected in the patient: a frameshift mutation in the SEMA4A gene (NM_001193300.2):c.2272_2273insT and a substitution in the SCP2 gene (NM_002979.5):c.712A>T. These mutations were confirmed in the parents and were not detected in the control group, which consists of 400 healthy people from the same ethnic group. In addition, such variants were absent from other published genetic databases, including 1000 Genomes, ExAc, gnomAD, and Iranome. Extensive bioinformatics analysis, the absence of these mutations in healthy human controls, and the early onset of symptoms confirm the pathogenicity of these variants.

Abstract 142 | PDF Downloads 67

References

1. Abid A, Ismail M, Mehdi S Q, Khaliq S, Identification of novel mutations in the SEMA4A gene associated with retinal degenerative diseases. J Med Genet. 2006;43:378–381.
2. Bryant L, Lozynska O, Han G, et al. On variants and disease-causing mutations: Case studies of a SEMA4A variant identified in inherited blindness. Ophthalmic Genetics. 2018;39:1, 144-146.
3. Nojima S, Toyofuku T, Kamao H, et al. Point mutation in Semaphorin 4A associates with defective endosomal sorting and causes retinal degeneration. Nat Commun. 2013;4:1406.
4. Rice DS, Huang W, Jones HA, et al. Severe retinal degeneration associated with disruption of semaphorin 4A. Invest Ophthalmol Vis Sci. 2004;45(8):2767-77.
5. Wan L, Deng B, Wu Z, Chen X. Exome sequencing study of 20 patients with high myopia. PeerJ. 2018;6:e5552.
6. Costa KA, Salles MV, Whitebirch C, Chiang J, Sallum JMF. Gene panel sequencing in Brazilian patients with retinitis pigmentosa. Int J Retina Vitreous. 2017;3:33.
7. Horvath R, Holinski‐Feder E, Neeve VC, et al. A new phenotype of brain iron accumulation with dystonia, optic atrophy, and peripheral neuropathy. Movement disorders. 2012;27(6):789-93.
8. Rodriguez AD, Prochazkova M, Santos SS, Cabezas OR, Extremera VC, Gonzalez-Gutierrez-Solana L. Early diagnosis of CAPOS syndrome before acute-onset ataxia—review of the literature and a new family. Pediatric Neurology. 2017;71:60-4.
9. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;1(5):589–595.
10. Yang H, Wang K. Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. Nat Protoc. 2015;10(10):1556–1566.
11. Tessier-Lavigne M, Goodman CS. The molecular biology of axon guidance. Science. 1996;274:1123–33.
12. Dickson BJ. Molecular mechanisms of axon guidance. Science. 2002;298:1959–1964.
13. Shi W, Kumanogoh A, Watanabe C, et al. The class IV semaphorin CD100 plays non-redundant roles in the immune system: defective B and T cell activation in CD100-deficient mice. Immunity. 2000;13:633–42.
14. Kumanogoh A, Marukawa S, Suzuki K, et al. Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2. Nature. 2002;419:629–33.
15. Guo XR, Zheng SC, Liu L, Feng QL. The sterol carrier protein 2/3-oxoacyl-CoA thiolase (SCPx) is involved in cholesterol uptake in the midgut of Spodoptera litura: gene cloning, expression, localization and functional analyses. BMC Molecular Biology. 2009;10(1):1-8.
16. Galano M, Venugopal S, Papadopoulos V. Role of STAR and SCP2/SCPx in the Transport of Cholesterol and Other Lipids. International Journal of Molecular Sciences. 2022;23(20):12115.
17. Horvath R, Lewis-Smith D, Douroudis K, et al. SCP2 mutations and neurodegeneration with brain iron accumulation. Neurology. 2015;85(21):1909-11.